

Background

- **Ten** bispecific T-cell engagers (BTCEs) have been approved in the US, with **more** currently in development.
- Approved agents are being explored for use in **earlier lines of therapy** and are expected to be used across a wider range of care settings.
- Differentiating BTCEs from other bispecific antibodies is **critical**, as they require **specific protocols** due to their unique dosing, monitoring schedules, and potential side effects.
- Many practice sites often **lack** the **confidence, education, and resources** necessary for their safe implementation.
- NCODA practice and member survey findings highlight **significant knowledge** and **confidence gaps** among practice sites:
 - **11%** can confidently **differentiate BTCEs** from non-T-cell bispecific antibodies.
 - **26%** feel confident in **managing** the **toxicities** associated with BTCEs.
 - **53%** face challenges in **transitioning patient care** between clinic and hospital.
- The NCODA Clinical Excellence Team:
 - Interviewed over **20 diverse clinical sites** and reviewed existing published playbooks and literature to identify operational gaps and resource needs.
 - Developed the Immunotherapy Hub to provide education, resources, and example protocols for the **safe and effective use of BTCEs** across various cancer care settings.

NCODA's Immunotherapy Hub: A Centralized Resource for Navigating Bispecific T-Cell Engagers

Madelyn Floysand, PharmD; Shawny Eugene, PharmD, MBA, MS; Kelly Brunk, PharmD, BCOP
NCODA, Cazenovia, New York

NCODA's Immunotherapy Hub is
your resource for all things
bispecific T-cell engager.



Scan QR Code to go to
download the **full abstract**



Scan QR Code to go to the
Immunotherapy Hub



Objective

Describe NCODA's Immunotherapy Hub, a resource created to fill operational gaps and support clinicians with education, protocols, and tools for safe and effective BTCE implementation.

Three Sections



1. Overview of BTCEs

- These resources provide essential knowledge on BTCEs, offering key insights and equipping you with practical guidance for effective clinical implementation.



2. Agent-Specific Resources

- "Up Close" resources let you dive deeper—offering focused insights on each BTCE.



3. Example SOPs & Documents

- De-identified example protocols, procedures, and resources.
- Collected from diverse clinic settings.

Future Directions

More Immunotherapy Resources:

- Chimeric Antigen Receptor T-cell (CAR-T)
- Immune Checkpoint Inhibitors
- Tumor Infiltrating Lymphocytes (TILs)
- Other emerging therapies

References

Scan the QR code to the left to access the full references list.